查看完整行情页>>

|

货币单位:美元(USD)

居里

Curis, Inc. (cris)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Kenneth I. Kaitin Dr. Kenneth I. Kaitin is an Independent Director at Curis, Inc. and a Director-Drug Development Study at Tufts Center for the Study of Drug Development. He is on the Board of Directors at Curis, Inc., Bio-Tree Systems, Inc., Centerphase Solutions, Inc. and QCDx LLC. Dr. Kaitin was previously employed as a Professor by Tufts University School of Medicine and a President by Drug Information Association. He also served on the board at Phase Forward, Inc., Erevnos Corp. and New England Healthcare Institute. He received his undergraduate degree from Cornell University, a graduate degree from the University of Rochester and a doctorate degree from the University of Rochester.
Martyn D. Greenacre Martyn D. Greenacre is a businessperson who has been the head of 8 different companies and presently occupies the position of Chairman for Life Mist Technologies, Inc. and Chairman at Curis, Inc. He is also on the board of Formula Pharmaceuticals, Inc. In the past Mr. Greenacre was Chairman of Life Mist LLC, Chairman for Acusphere, Inc., Chief Executive Officer & Director at Delsys Pharmaceutical Corp., Chairman of Beijing Med-Pharm Corp., Chairman of BMP Sunstone Corp., President & Chief Executive Officer at Zynaxis, Inc., Senior Advisor at Arsenal Capital Management LP, Director & Chairman-European Operations at Smithkline Beecham Pharmaceuticals (India) Ltd. and Member-Executive Committee at Applera Corp. He received an MBA from Harvard Business School and an undergraduate degree from Harvard College.
James E. Dentzer Currently, James E. Dentzer is President, Chief Executive Officer & Director at Curis, Inc. In his past career he occupied the position of Chief Financial Officer at Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., Controller for Biogen, Inc., Chief Financial Officer for Valeritas, Inc. and Chief Financial Officer-DuPont Flooring Systems at E.I. du Pont de Nemours & Co. Mr. Dentzer received an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
Marc Rubin Marc Rubin is a businessperson who has been at the helm of 5 different companies. Currently, he is Executive Chairman at Titan Pharmaceuticals, Inc. He is also on the board of 5 other companies. Dr. Rubin previously held the position of President & Chief Executive Officer of Titan Pharmaceuticals, Inc., Senior Vice President-Global Clinical Pharmacology at GlaxoSmithKline Plc, Chairman of Schering Berlin, Inc., President at Berlex Pharmaceuticals, Inc., Head-Global Research & Development at Bayer Pharma AG and Head-Global Research & Development at Bayer Schering Pharma AG. Dr. Rubin received a doctorate from Weill Cornell Medical College.
Lori Anne Kunkel Lori Anne Kunkel is on the board of Curis, Inc., Tocagen, Inc., Nurix Therapeutics, Inc. and Maverick Therapeutics, Inc. and Owner at Lak505, LLC. She previously was Chief Medical Officer for Syndax Pharmaceuticals, Inc., Vice President-Clinical Development at Xencor, Inc., Chief Medical Officer for ACT Biotech, Inc., Principal at XOMA Corp., Vice President-Medical Affairs for Genitope Corp., Director at Loxo Oncology, Inc., Chief Medical Officer for Proteolix, Inc., Chief Medical Officer of Pharmacyclics LLC, Principal at Salmedix, Inc., Principal at Onyx Pharmaceuticals, Inc., Head-Clinical Scientist at Genentech, Inc., Principal at DNAX Research Institute of Molecular & Cellular Biology, Inc, Principal at ZymoGenetics, Inc., Associate Director-Clinical Development at Chiron Corp. and Member-Bone Marrow Transplant Unit at the University of California. Dr. Kunkel received an undergraduate degree from the University of California San Diego and a doctorate from the University of Southern California.
Robert E. Martell Robert E. Martell founded Epi-Cure Pharmaceuticals, Inc. Presently, he is Head-Research & Development at Curis, Inc. He is also Member of American Association for Cancer Research, Associate Chief-Division of Hematology/Oncology at Tufts Medical Center, Inc., Professor at Tufts University School of Medicine and Member of American Society of Clinical Oncology. In his past career Robert E. Martell was President & Director at Epi-Cure Pharmaceuticals, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Chief Medical Officer & Vice President at Mirati Therapeutics, Inc., Chief Medical Officer at TESARO, Inc., Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Associate Professor at Tufts Medical Center, Inc., Assistant Professor at Duke University Medical Center, Assistant Clinical Professor at Yale School of Medicine and Director-Neely Center at Clinical Cancer Research. Robert E. Martell received an undergraduate degree from Kalamazoo College, a doctorate from the University of Michigan and a doctorate from Wayne State University (Michigan).
Rachel S. Blasbalg Currently, Rachel S. Blasbalg occupies the position of Senior Director-Human Resources at Curis, Inc.
William E. Steinkrauss William E. Steinkrauss holds the position of Chief Financial Officer & Treasurer for Curis, Inc. In the past Mr. Steinkrauss occupied the position of Director-Technical Accounting & Reporting at OvaScience, Inc. and Senior Manager-Technical Accounting at Cubist Pharmaceuticals LLC. He received a graduate degree and an undergraduate degree from Boston College.
Reinhard von Roemeling Presently, Reinhard von Roemeling is Senior Vice President-Clinical Development at Curis, Inc. He received a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Christine Guertin Presently, Christine Guertin is VP-Regulatory Affairs & Quality Assurance at Curis, Inc. She received an undergraduate degree from Saint Joseph's College (Indiana) and a graduate degree from Regis College.
Nancy Soohoo Nancy Soohoo is General Counsel of Curis, Inc.